S2A:5 DEVELOPMENT AND VALIDATION OF A SCORE TO PREDICT THE RISK OF SEVERE INFECTION IN SLE

¹B Segura, ²I Rúa-Figueroa, ³JM Pego-Reigosa, ⁴V Del Campo, ⁵D Isenberg, ⁵A Rahman.
¹Insular University Hospital, Rheumatology Department, Las Palmas de Gran Canaria, Spain;
²Doctor Negrín University Hospital, Rheumatology Department, Las Palmas de Gran Canaria, Spain; ³Biomedical Research Institute of Vigo (IBIV), University Hospital Complex of Vigo, Rheumatology Department, Vigo, Spain; ⁴Biomedical Research Institute of Vigo (IBIV), University Hospital Complex of Vigo, Preventive Medicine Department, Vigo, Spain; ⁵University College London Hospital, Centre for Rheumatology, Department of Medicine, London, UK

10.1136/lupus-2018-abstract.8

Purpose To develop a predictive risk score that assesses the probability of severe infection in SLE patients and to test it in an independent cohort.

Methods The SLE severe infection score (SLEIS) was developed using data from the RELESSER (Spanish Society of Rheumatology Lupus Registry) cohort of 3658 SLE patients using a Cox regression model for repeated events (Andersen-Gill). The results were expressed as hazard ratio (HR) of developing one serious infection/1000 patient-years for patients with the risk factor compared to those without that factor. SLEIS for an individual patient is the sum of the HR values of all factors present at that time.

SLEIS was validated using retrospective data from the UCLH (University College London Hospital) cohort including 699 SLE patients.

Results The risk factors included in SCORE and their HR calculated from RELESSER data are shown in table 1. From 699 SLE UCLH patients, 98 (14%) developed serious infection.

Abstract S2A:5 Table 1

Risk factor	B	P-value	HR
Age at diagnosis (>46 years old)	0.1163	0.001	1.12
Latin American ethnicity	0.427	0.001	2.40
Corticosteroids (>10 mg/day) at time of calculating SCORE	0.2878	0.001	1.33
Sex=male	0.3692	0.0001	1.49
Previous hospitalization (for SLE)	1.0049	<0.00001	2.73
Katz index	0.062	0.002	1.06
Prior infection at any time	0.8739	<0.0001	2.40

We compared these patients with 111 SLE controls who never suffered serious infection. The characteristics of the SLE infection and SLE non-infection groups are summarised in table 2.

Median SLEIS at diagnosis in patients with infection was 4.27 (IQR 3.18) which was significantly higher than in the control group (Median 2.55, IQR 3.79) ($z=3.341$; $p=0.0008$). Median SLEIS just before infection was 5.3 (IQR 3.68) which was significantly higher compared to SLEIS at diagnosis ($z=-5.733$; $p\leq 0.001$) in those patients or SLEIS measured at the same time post-diagnosis in the non-infected group (Median 3.73 RI 3.7) ($z=-4.765$, $p\leq 0.001$).

By Receiver Operator Characteristic analysis, we defined three possible cut-offs to distinguish patients with and without infection. For SLEIS just before infection, the area under the ROC curve was 0.75 (CI: 0.66 to 0.84) and the three selected cut offs (3.67, 3.79, 4.24) reached a sensitivity of 90% and specificity of 50%.

Conclusion We have developed a score for predicting risk of serious infection in SLE and validated it in an independent cohort. Given the potential mortality from such infections, SLEIS could be clinically useful though the moderate sensitivity and specificity necessitate caution and further prospective studies.

S2A:6 SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (SUPAR) PREDICTS THE DEVELOPMENT OF ORGAN DAMAGE OVER 5 YEARS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE SLICC INCEPTION COHORT

¹H Enocsson, ¹L Wirestam, ¹J Wetterö, ¹T Skogh, The Slicc Group², ^{3,4}IN Bruce, ¹C Sjöwall.
¹Rheumatology, Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine Linköping Uni, Linköping, Sweden; ²The Systemic Lupus International Collaborating Clinics (SLICC) Group; ³Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK; ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

10.1136/lupus-2018-abstract.9

Background The urokinase plasminogen activator receptor (suPAR) participates in proteolysis, migration and adhesion. Receptor shedding yields a soluble form (suPAR) that has emerged as a promising severity biomarker in malignancies, inflammatory and infectious diseases. Previously, suPAR was shown to reflect accumulated organ damage in systemic lupus erythematosus (SLE). Here, we investigate suPAR as a potential predictor of future organ damage in patients with recent-onset SLE.

Methods 345 SLE cases (at least 4 ACR criteria) from North America, Europe and Asia were included. All patients were from the SLICC inception cohort and were selected based on a minimum of 5 years follow-up and absence of organ damage (SLICC/ACR damage index; SDI>0) at inclusion. Patients were enrolled within 15 months of diagnosis. Estimated glomerular filtration rate (eGFR) was available for 180 patients. Serum suPAR levels were measured by ELISA at inclusion only, and levels were related to SDI after 5 years of follow-up. Age- and sex-matched controls (1:1) were from the Swedish population.

Abstract S2A:5 Table 2

	SLE-infection (n=98)	SLE-non infection (n=111)	P value
Gender, n (%)	- Females: 90 (91.8) - Males: 8 (8.2)	- Females: 103 (92.8) - Males: 8 (7.2)	ns
Median age at diagnosis of SLE (IQR)	30.5 (27)	31 (18)	ns
Mean age at time of infection (IQR)	43 (25)		
Ethnicity, n (%)			
Caucasian	48 (49)	72 (64.9)	ns
Latin American	3 (3.06)	2 (1.8)	
Afro-Caribbean	28 (28.6)	20 (18.02)	
Asian	7 (7.1)	6 (5.4)	
Other	12 (12.2)	12 (10.8)	
Median length of follow-up (IQR)	9.5 (14) yrs	14 (9) yrs	ns
Previous infection before SLE diagnosis, n (%)	16 (16.3)	3 (2.7)	0.001
Previous hospitalizations (SLE), n (%)	55 (56.1)	36 (32.4)	0.001
SLE main features (cumulative), n (%)	- Skin disease 76 (77.6) - Joint disease 72 (73.5) - Renal disease 42 (42.9) - CNS disease 13 (13.1) - Serositis 19 (19.4)	- Skin disease 67 (60.3) - Joint disease 101 (90.5) - Renal disease 29 (26.1) - CNS disease 12 (10.8) - Serositis 33 (29.7)	- 0.012 - 0.001 - 0.011 ns ns
Laboratory findings (cumulative), n (%)	- Neutropenia 33 (33.7) - Lymphopenia 76 (77.6) - Decreased C3/C4 levels 57 (58.2) - Elevated dsDNA-Ab 67 (68.4)	- Neutropenia 19 (17.1) - Lymphopenia 73 (65.8) - Decreased C3/C4 levels 50 (45.1) - Elevated dsDNA 66 (60)	0.006 ns ns ns
Previous drug treatment, n (%)	- Steroids (at any time) 89 (90.8) - No Hydroxychloroquine 32 (32.7) - MMF 36 (34.7) - AZA 47 (48) - Cyclophosphamide 28 (28.6) - Biological treatment 26 (26.5)	- Steroids (at any time) 43 (38.7) - No Hydroxychloroquine 25 (25.2) - MMF 28 (25.2) - AZA 35 (26.1) - Cyclophosphamide 13 (11.7) - Biological treatment 25 (22.5)	<0.001 ns ns 0.02 <0.001 ns
Patients with >1 Infection	18 (18.4%)		
Death following infection	26 (26.5%)		

Results Baseline suPAR levels were higher in patients who acquired damage (SDI>1) over a 5 year period (n=33) compared to patients without damage development (n=246; p<0.001) and controls (n=345; p=0.007) (figure 1). There were no significant differences in suPAR with regard to ethnicity (Caucasians vs non-Caucasians) or sex in patients/controls, but a weak correlation between age and suPAR among controls (p<0.001, r=0.23). No correlations (r>0.2) were found between suPAR and disease activity (SLEDAI-2K), corticosteroid dose or eGFR. Logistic regression revealed significant impact of baseline suPAR on future damage (SDI>1) (p=0.014; area under curve, AUC=0.64) and the predictive value became

stronger after adjustment for age, sex, ethnicity and corticosteroid dose (p=0.008; AUC=0.74). Examining individual components of SDI revealed significant impact of suPAR on musculoskeletal damage (SDI>0) (p=0.018; AUC=0.66) also when adjusting for covariates (p=0.020; AUC=0.68).

Conclusion Prognostic biomarkers of disease severity in SLE could identify patients in need of tight control and improved treatment strategies. Here, suPAR is for the first time shown to have predictive potential of damage accrual in SLE. Continued follow-up of patients could elucidate the association between suPAR and damage in specific organ domains.

Abstract S2A:6 Figure 1

S2d – Lupus nephritis

S2D:5 EXOSOMES TARGET RENAL TUBULAR EPITHELIAL CELLS TRANSFERRING INFLAMMATORY EPSTEIN-BARR VIRUS-ENCODED SMALL RNA (EBER1) IN LUPUS NEPHRITIS PATIENTS

¹SR Baglio, ¹N Masoumi, ²MW Tsang-a-Sjoe, ¹MA van Eijndhoven, ³KM Heutink, ¹ES Jordanova, ⁴RJ ten Berge, ⁵K Grundberg, ⁶RM Schiffelers, ¹J van den Wetering, ¹K de Wildt, ¹SM Verkuijlen, ⁷J Roelofs, ²IE Bultink, ¹JM Middeldorp, ²AE Voskuyl, ¹DM Pegtel. ¹Department of Pathology, Exosomes Research Group, VU University Medical Centre, Amsterdam, The Netherlands; ²Amsterdam Rheumatology and immunology Centre at VU University Medical Centre, Amsterdam, The Netherlands; ³Department of Nephrology, VU University Medical Centre, Amsterdam, The Netherlands; ⁴Department of Internal Medicine, Experimental Immunology and Renal Transplant Unit, Amsterdam, The Netherlands; ⁵Department of Pathology, Radboud University, Nijmegen, The Netherlands; ⁶Department of Clinical Chemistry, Utrecht University, Amsterdam, The Netherlands; ⁷Department of Pathology, Academic Medical Centre, Amsterdam, The Netherlands

10.1136/lupus-2018-abstract.10

In systemic lupus erythematosus (SLE) antiviral defenses are chronically activated, resulting in over-activity of the type I interferon (IFN) pathway. Studies in lupus-prone mice suggest that immune complexes associated with endogenous nucleic acids drive renal inflammation, a major cause of SLE-morbidity. However, the origin and nature of the extracellular nucleic acids driving inflammation in human lupus nephritis (LN) are incompletely understood.

Here we provide evidence that extracellular vesicles (EVs) can deliver a pro-inflammatory small RNA cargo into renal tubular epithelial cells (TECs). *In situ* RNA hybridization for Epstein-Barr virus (EBV)-encoded small RNAs (EBER-ISH) on LN tissue biopsies revealed atypical EBER localization in the cytoplasm of TECs. Stem-loop RT-PCR confirmed the presence of intact 167nt EBV-EBER1 RNA in LN tissues while EBV-DNA was virtually undetectable, arguing against EBV-infected (B) cells as an explanation for EBER1 detection. We hypothesised that cell-free EBER1 in circulation enters the renal tubular epithelium in predisposed individuals. We detected extracellular vesicle (EV) associated EBER1 in SLE patient sera but not in healthy and disease controls. We determined primary TEC express phosphatidylserine (PS) receptors, most notably Kidney-injury molecule-1 (KIM1), that support endocytosis of EBER1-loaded EVs. Purified EVs from EBV-infected B cells trigger an interferon stimulated gene expression (ISG) signature in TEC that is also expressed in LN tissues, but absent in renal disease control tissues. Immunohistochemistry further reveals TLR3 and KIM-1 protein expression in the renal epithelium of LN tissues. Importantly, hydroxychloroquine and Toll-like receptor-3 (TLR3) blockade inhibit EBER1-induced pro-inflammatory cytokine (IL-6 and TNFα) production in primary TECs. We propose that PS-mediated EV uptake by TECs and TLR3-mediated recognition of EBER1 induces pro-inflammatory cytokine expression may aggravate renal inflammation in human SLE. Our findings support the rationale for therapeutic blockade of TLR signalling in LN patients. Taken together our observations

Abstract S2D:5 Figure 1 Renal epithelial cells internalise EBV-exosomes in a phosphatidylserine (PS)-dependent manner